Unique ID issued by UMIN | UMIN000010955 |
---|---|
Receipt number | R000012819 |
Scientific Title | Multicenter prospective observation study of salvage-line bevacizumab for unresectablemetastatic colorectal cancer in Okayama |
Date of disclosure of the study information | 2013/06/13 |
Last modified on | 2018/06/25 14:58:09 |
Multicenter prospective observation study of salvage-line bevacizumab for unresectablemetastatic colorectal cancer in Okayama
MAYUMI trial
Multicenter prospective observation study of salvage-line bevacizumab for unresectablemetastatic colorectal cancer in Okayama
MAYUMI trial
Japan |
Colorectal Cancer
Gastroenterology | Gastrointestinal surgery |
Malignancy
NO
Observational Study of Bevacizumab with Chemotherapy for Patients Refractory or Intolerable to Oxaliplatin and Irinotecan with Unresectable/Recurrent Colorectal Cancer
Safety,Efficacy
PFS; progression-free survival
OS; overall survival
TTF; time to treatment-failure
ORR; overall response rate
Safty
Observational
Not applicable |
Not applicable |
Male and Female
1. Unresectable/recurrent colorectal cancer patients, who are refractory or intolerable to oxaliplatin and irinotecan, intended to recieve any chemotherapies with bevacizumab.
2. Evaluable of the effectiveness of the treatment by image.
3. Evaluable of the safty of the treatment.
4. Be able to provide a clinical examination information.
5. Be able to do the following treatement, any chemotharapise with Bevacizumab 2.5mg/kg/week or 5.0mg/kg/week.
None
60
1st name | |
Middle name | |
Last name | Toshiyoshi Fujiwara |
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Department of Gastroenterological Surgery
2-5-1, Shikata-cho, Kita-ku, Okayama, Japan
086-235-7257
1st name | |
Middle name | |
Last name | Takeshi Nagasaka |
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Department of Gastroenterological Surgery
2-5-1, Shikata-cho, Kita-ku, Okayama, Japan
086-235-7257
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Self funding
NO
2013 | Year | 06 | Month | 13 | Day |
Unpublished
Completed
2013 | Year | 05 | Month | 29 | Day |
2013 | Year | 06 | Month | 13 | Day |
This study aimed to examine the effectiveness and safety of chemotherapies with bevacizumab after the third-line treatment for unresectable advanced colon cancer.
(primary endpoint)
PFS; progression-free survival
(secondly endpoint)
OS; overall survival
TTF; time to treatment-failure
ORR; overall response rate
Safty
2013 | Year | 06 | Month | 13 | Day |
2018 | Year | 06 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012819
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |